Literature DB >> 18839024

Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion.

Zhi-You Cai1, Yong Yan, Shan-Quan Sun, Jun Zhang, Liang-Guo Huang, Ning Yan, Fang Wu, Jie-Ying Li.   

Abstract

OBJECTIVE: Nitric oxide (NO) was speculated to play an important role in the pathophysiology of cerebral ischemia. Minocycline, a tetracycline derivative, reduced inflammation and protected against cerebral ischemia. To study the neuroprotection mechanism of minocycline for vascular dementia, the influences of minocycline on expressions of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) were observed in the brains of Wistar rats.
METHODS: The vascular dementia rat model was established by permanent bilateral common carotid arteries occlusion (BCCAO). Wistar rats were divideded into 3 groups randomly: sham-operation group (S group), vascular dementia model group (M group), and minocycline treatment group (MT group). The behaviour was tested with Morris water maze and open-field task. Expressions of iNOS and eNOS were measured by immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR). The optical density value was measured by imaging analysis. Percentage of positive cells with iNOS and eNOS expression was analyzed with optical microscope.
RESULTS: Minocycline attenuated cognitive impairment. Inducible NOS was significantly down-regulated in MT group, compared with that in M group (P < 0.01), while eNOS was significantly up-regulated, compared with that in M group (P < 0.01). The expressions of iNOS and eNOS in M and MT groups were higher than those in S group (P < 0.01).
CONCLUSION: Minocycline can down-regulate the expression of iNOS and up-regulate the expression of eNOS in vascular dementia, which restrains apoptosis and oxidative stress to protect neural function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18839024      PMCID: PMC5552530          DOI: 10.1007/s12264-008-0324-y

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  24 in total

Review 1.  Apoptotic cascades as possible targets for inhibiting cell death in Huntington's disease.

Authors:  Lindsay R Pattison; Mark R Kotter; Dean Fraga; Raphael M Bonelli
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

2.  Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models.

Authors:  Yoori Choi; Hye-Sun Kim; Ki Young Shin; Eun-Mee Kim; Minji Kim; Hyun-Soo Kim; Cheol Hyoung Park; Yun Ha Jeong; Jongman Yoo; Jean-Pyo Lee; Keun-A Chang; Seonghan Kim; Yoo-Hun Suh
Journal:  Neuropsychopharmacology       Date:  2007-04-04       Impact factor: 7.853

3.  Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury.

Authors:  R M Pluta; R Rak; D A Wink; J J Woodward; A Khaldi; E H Oldfield; J C Watson
Journal:  Neurosurgery       Date:  2001-04       Impact factor: 4.654

4.  Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro.

Authors:  Midori A Yenari; Lijun Xu; Xian Nan Tang; Yanli Qiao; Rona G Giffard
Journal:  Stroke       Date:  2006-02-23       Impact factor: 7.914

5.  Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons.

Authors:  S Lin; Y Zhang; R Dodel; M R Farlow; S M Paul; Y Du
Journal:  Neurosci Lett       Date:  2001-11-23       Impact factor: 3.046

6.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

7.  Microsphere embolism-induced endothelial nitric oxide synthase expression mediates disruption of the blood-brain barrier in rat brain.

Authors:  Feng Han; Yasufumi Shirasaki; Kohji Fukunaga
Journal:  J Neurochem       Date:  2006-10       Impact factor: 5.372

Review 8.  Free radical pathways in CNS injury.

Authors:  A Lewén; P Matz; P H Chan
Journal:  J Neurotrauma       Date:  2000-10       Impact factor: 5.269

9.  Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury.

Authors:  David P Stirling; Kourosh Khodarahmi; Jie Liu; Lowell T McPhail; Christopher B McBride; John D Steeves; Matt S Ramer; Wolfram Tetzlaff
Journal:  J Neurosci       Date:  2004-03-03       Impact factor: 6.167

10.  Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease.

Authors:  Xin Wang; Shan Zhu; Martin Drozda; Wenhua Zhang; Irina G Stavrovskaya; Elena Cattaneo; Robert J Ferrante; Bruce S Kristal; Robert M Friedlander
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

View more
  26 in total

1.  Intracranial electrode implantation produces regional neuroinflammation and memory deficits in rats.

Authors:  Yafit Kuttner Hirshler; Uri Polat; Anat Biegon
Journal:  Exp Neurol       Date:  2009-12-21       Impact factor: 5.330

Review 2.  Rodent Models of Vascular Cognitive Impairment.

Authors:  Yi Yang; Shihoko Kimura-Ohba; Jeffrey Thompson; Gary A Rosenberg
Journal:  Transl Stroke Res       Date:  2016-08-08       Impact factor: 6.829

3.  Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats.

Authors:  Harikesh Kalonia; Jitendriya Mishra; Anil Kumar
Journal:  Neurotox Res       Date:  2012-03-06       Impact factor: 3.911

4.  Role of interleukin-1beta in postoperative cognitive dysfunction.

Authors:  Mario Cibelli; Antonio Rei Fidalgo; Niccolò Terrando; Daqing Ma; Claudia Monaco; Marc Feldmann; Masao Takata; Isobel J Lever; Jagdeep Nanchahal; Michael S Fanselow; Mervyn Maze
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

5.  Anti-inflammatory properties of doxycycline and minocycline in experimental models: an in vivo and in vitro comparative study.

Authors:  Liz M Leite; Antônio Germano G Carvalho; Pollyanna L F Tavares Ferreira; Igor Xavier Pessoa; Danilo O Gonçalves; Amanda de Araújo Lopes; Jean Guilherme dos Santos Góes; Victor Costa de Castro Alves; Luzia Kalyne A M Leal; Gerly Anne Brito; Glauce S B Viana
Journal:  Inflammopharmacology       Date:  2011-02-25       Impact factor: 4.473

6.  Hypoxia-induced neuroinflammatory white-matter injury reduced by minocycline in SHR/SP.

Authors:  Fakhreya Y Jalal; Yi Yang; Jeffrey F Thompson; Tamara Roitbak; Gary A Rosenberg
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-25       Impact factor: 6.200

Review 7.  The mechanisms of brain ischemic insult and potential protective interventions.

Authors:  Zhao-Hui Guo; Feng Li; Wei-Zhi Wang
Journal:  Neurosci Bull       Date:  2009-06       Impact factor: 5.203

8.  Anxiety after cardiac arrest/cardiopulmonary resuscitation: exacerbated by stress and prevented by minocycline.

Authors:  Gretchen N Neigh; Kate Karelina; Erica R Glasper; Stephanie L K Bowers; Ning Zhang; Phillip G Popovich; A Courtney DeVries
Journal:  Stroke       Date:  2009-09-17       Impact factor: 7.914

9.  A cognitive rehabilitation paradigm effective in male rats lacks efficacy in female rats.

Authors:  Kristopher D Langdon; Shirley Granter-Button; Carolyn W Harley; Frances Moody-Corbett; James Peeling; Dale Corbett
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-23       Impact factor: 6.200

10.  Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease.

Authors:  Cai Zhiyou; Yan Yong; Sun Shanquan; Zhang Jun; Huang Liangguo; Yan Ling; Li Jieying
Journal:  Neurochem Res       Date:  2009-01-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.